Chronic lymphocytic leukemia

MS Gentile; A Guarini; FR Mauro; R Foà

doi:10.4081/hmr.v1i8.284

Articles

3 June 2009

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005

https://doi.org/10.4081/hmr.v1i8.284

Chronic lymphocytic leukemia

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

195

Views

390

Downloads

Authors

MS Gentile

support@pagepress.org

A Guarini

FR Mauro

R Foà

Chronic lymphocytic leukemia (CLL) is a disorder characterized by a progressive accumulation of mature B lymphocytes which either avoid death because of external survival signals or go into apoptosis to be replenished by proliferating precursors. CLL is the most common type of leukemia of elderly people in the Western countries.1 Although the median survival is around 10 years, in individual patients the prognosis is extremely variable, ranging from a very short to a normal life span. After decades during which the wait and watch management has been the normal approach to these patients, the attitude of the physicians towards CLL patients has changed remarkably during the last few years. The reasons for this change are manifold and some are discussed below.